Tylenol v. Advil: who'll come out on top?

Johnson & Johnson said it's returning some versions of children's and infant's Tylenol to stores after recalling millions of bottles earlier this year. How the brand fares may depend on the degree to which it can hold onto consumer loyalty.
Researchers from The Relational Capital Group and Princeton University surveyed 1,042 US consumers and found that the Tylenol brand slightly outpaces Pfizer's Advil in consumer loyalty (67% vs. 65% positive) and purchase intent (76% vs. 75% positive).

Respondents rated both brands equally well on such statements “is honest and trustworthy” and “acts with your best interest in mind.” These dimensions were shown to impact purchase intent and loyalty.  

Chris Malone, chief advisory officer of The Relational Capital Group, said consumers have interpreted J&J's quality control problems as “a temporary lapse in competence.”
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


Investment in healthcare IT stands at an all-time high. The government has spent billions to promote EHR adoption. Yet the physician wish list is a mile long, while hospitals and patients are not where they need to be. To peel back the layers of what we've all been waiting for in the Great Data Capture of the 21st Century, and to review the changes enabling the healthcare data ecosystem to coexist, MM&M presents this e-Book. Click here.


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.